Cohance Lifesciences promoters, Jusmiral and Berhyanda Holdings, have secured a new $285 million term loan facility, effective June 11, 2026. This refinancing replaces prior agreements and involves pledging 207,974,582 shares. While managing debt, a high promoter pledge ratio remains a key watch point.

Cohance Lifesciences: Promoters Secure $285 Million Facility, Maintain High Share Pledges

Total Facility Amount: USD 285,000,000
Total Pledged Shares: 207,974,582

Reader Takeaway: Debt refinanced through pledging; high promoter pledge ratio persists.

What just happened

Cohance Lifesciences Ltd announced a new term loan facility agreement executed on June 11, 2026, amounting to USD 285 million. As part of this refinancing, promoters Jusmiral Holdings Limited and Berhyanda Limited created new encumbrances on a total of 207,974,582 shares of the company. This action effectively releases prior encumbrances made under a Notes Purchase Agreement dated May 29, 2024.

The consortium providing these new facilities includes prominent banks: Barclays Bank, Deutsche Bank, BNP Paribas, MUFG Bank, and Standard Chartered Bank.

Why this matters

This move confirms the company's promoters are actively managing their debt obligations. The refinancing provides a structured way to handle existing liabilities. However, the continued high level of promoter share pledging remains a significant factor for investors to monitor due to the inherent risks associated with such arrangements.

The backstory

The filing indicates a refinancing exercise that replaces an older agreement from May 2024. The promoters, Jusmiral Holdings and Berhyanda Limited, have consistently utilized their shareholding as collateral for debt.

What changes now

With the new facility in place, the immediate debt servicing structure for the promoters has been updated. The release of old encumbrances and creation of new ones streamlines the collateral management. The company itself is not directly raising this debt, but its promoters are.

Risks to watch

The most critical watch point for investors is the substantial promoter share pledging. A total of 207,974,582 shares are pledged, representing a significant portion of the promoters' total stake. Investors should be vigilant about potential implications if debt covenants are breached or if market volatility impacts the collateral's value, potentially leading to invocation of these pledged shares.

Peer comparison

While specific peer refinancing details are not provided in the filing, high promoter pledging is a common, though watched, financial strategy in certain market conditions among Indian listed companies.

Context metrics (time-bound)

• New Facility Agreement Date: June 11, 2026
• Promoter Share Pledging Effective Date: June 16, 2026
• Previous Notes Purchase Agreement Date: May 29, 2024
• Total Facility Amount: USD 285,000,000
• Total Pledged Shares (Jusmiral): 80,434,990
• Total Pledged Shares (Berhyanda): 127,539,592
• Total Pledged Shares: 207,974,582

What to track next

Investors should closely monitor future disclosures from Cohance Lifesciences regarding the status of these pledged shares, any changes in debt covenants, and the overall financial health of the promoters.